Search

Your search keyword '"Aastha Agarwal"' showing total 2 results
Start Over Author "Aastha Agarwal" Journal international journal of infectious diseases
2 results on '"Aastha Agarwal"'

1. Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences

Author

Snigdha Saxena, Ananta Khurana, Savitha B, Kabir Sardana, Aastha Agarwal, Aishwarya Muddebihal, Alok Raina, and Purnima Paliwal

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Type 2 leprosy reaction (T2LR), or Erythema Nodosum Leprosum (ENL), often poses a therapeutic challenge to clinicians and commonly requires long courses of steroids for control. While immunosuppressants are known to achieve control and lower steroid dependence in T2LR, the prospect of managing a severe T2LR in conjunction with COVID-19, with the concern of worsening COVID-19 with long-term immunosuppression has not previously been encountered. We report a case of severe T2LR treated with oral steroids and methotrexate, with COVID-19 infection acquired during hospital stay, and a favourable outcome achieved despite the continued use of immunosuppressants. We discuss the possible reasons for this both in terms of the drug pharmacodynamics and the immunological profile of T2LR.

Published
2021
Full Text
View/download PDF

2. Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences

Author

Ananta Khurana, Savitha B, Kabir Sardana, Aishwarya Muddebihal, Aastha Agarwal, Alok Raina, Snigdha Saxena, and Purnima Paliwal

Subjects
0301 basic medicine, Drug, Microbiology (medical), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, media_common.quotation_subject, 030106 microbiology, Case Report, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, lcsh:RC109-216, 030212 general & internal medicine, Intensive care medicine, media_common, business.industry, Immunosuppression, General Medicine, medicine.disease, Erythema nodosum leprosum, Infectious Diseases, Pharmacodynamics, Methotrexate, Leprosy, business, Hospital stay, medicine.drug
Abstract

Type 2 leprosy reaction (T2LR), or Erythema Nodosum Leprosum (ENL), often poses a therapeutic challenge to clinicians and commonly requires long courses of steroids for control. While immunosuppressants are known to achieve control and lower steroid dependence in T2LR, the prospect of managing a severe T2LR in conjunction with COVID-19, with the concern of worsening COVID-19 with long-term immunosuppression has not previously been encountered. We report a case of severe T2LR treated with oral steroids and methotrexate, with COVID-19 infection acquired during hospital stay, and a favourable outcome achieved despite the continued use of immunosuppressants. We discuss the possible reasons for this both in terms of the drug pharmacodynamics and the immunological profile of T2LR.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results